Epsilen Bio is a biotechnology company developing transformative therapies for patients affected by underserved medical conditions, through stable and long-lasting epigenetic silencing of genes involved in pathological processes. Based in Milan, Italy, Epsilen Bio was founded in December 2019 by the renowned gene therapy experts Prof. Angelo Lombardo and Prof. Luigi Naldini, The Telethon Foundation and San Raffaele Hospital. Epsilen Bio is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute, and received seed funding from Sofinnova Partners. For more information, please visit: www.epsilenbio.com
Paola Pozzi joined Sofinnova Partners in 2018 as Partner for the Sofinnova Telethon Fund, Italy’s first biotechnology fund focused on rare and genetic diseases. Prior to that, she was Head of the Office of Biotechnology Transfer of Ospedale San Raffaele, an internationally renowned research university hospital based in Milan.